Amprius Technologies, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
On August 18, 2025, Dr. Kang Sun, our Chief Executive Officer, entered into a stock trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 Plan”), which has an end date of December 31, 2026. Dr. Sun’s Rule 10b5-1 Plan provides for the potential sale of up to 7,217,869 shares of our common stock.
On September 11, 2025, Dr. Constantin Ionel Stefan, our Chief Technology Officer, entered into a Rule 10b5-1 Plan, which has an end date of March 10, 2027. Dr. Stefan’s Rule 10b5-1 Plan provides for the potential sale of up to 915,562 shares of our common stock.
During the quarter ended September 30, 2025, no other director or officer, as defined in Rule 16a-1(f), adopted orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.